0001209191-17-057220.txt : 20171017 0001209191-17-057220.hdr.sgml : 20171017 20171017191927 ACCESSION NUMBER: 0001209191-17-057220 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20171013 FILED AS OF DATE: 20171017 DATE AS OF CHANGE: 20171017 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Keyes Jason A CENTRAL INDEX KEY: 0001678152 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33415 FILM NUMBER: 171141610 MAIL ADDRESS: STREET 1: 3344 NORTH TORREY PINES COURT STREET 2: SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Orexigen Therapeutics, Inc. CENTRAL INDEX KEY: 0001382911 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 651178822 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3344 N. TORREY PINES CT. STREET 2: SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (858) 875-8600 MAIL ADDRESS: STREET 1: 3344 N. TORREY PINES CT. STREET 2: SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-10-13 0 0001382911 Orexigen Therapeutics, Inc. OREX 0001678152 Keyes Jason A 3344 NORTH TORREY PINES COURT SUITE 200 LA JOLLA CA 92037 0 1 0 0 EVP, Chief Financial Officer Restricted Stock Unit (RSU) 2017-10-13 4 A 0 69600 0.00 A Common Stock 69600 69600 D Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. Reflects an award of restricted stock units ("RSUs"), each representing a contingent right to receive a share of the issuer's common stock upon settlement. Twenty-five percent (25%) of the RSUs will vest on each of the first four (4) anniversaries of February 3, 2018 (each, a "Vesting Date"), subject to the reporting person's continued eligibility on each applicable Vesting Date. Thomas P. Lynch, as Attorney-in-Fact for Jason A. Keyes 2017-10-17 EX-24.4_748544 2 poa.txt POA DOCUMENT Power of Attorney For Section 16(a) Securities and Exchange Act of 1934 Filings Know all by these presents, that the undersigned hereby constitutes and appoints each of Thomas P. Lynch and Stephen A. Moglia, signing singly, the undersigned's true and lawful attorney-in-fact to: (1) Do and perform all acts for and on behalf the undersigned which may be necessary or desirable to apply for, obtain and/or maintain EDGAR Access Codes to be used on behalf of the undersigned for Electronic Filing of all Section 16(a) Securities and Exchange Act of 1934 filings; (2) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Orexigen Therapeutics, Inc. (the "Company"), Forms 3, 4, and 5 and any amendments thereto in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder; (3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 23rd day of June, 2016. Signature: Print Name: Jason Andrew Keyes